C Ray Therapeutics focuses on discovery, development, and manufacturing of radiopharmaceuticals including targeted Radionuclide Drug Conjugates (RDCs) and alpha-emitting therapies. The company operates a nearly 30,000 square meter R&D and production base and holds the first Class A Radiation Safety License for an innovative radiopharmaceutical enterprise. Its platform includes 13 cGMP-standard radiopharmaceutical production workshops, permits to handle over 30 medical isotopes, and automated production lines compliant with FDA, NMPA, and EMA standards. C Ray offers one-stop customized services spanning molecular imaging CRO work, companion diagnostics, target validation, and full CRDMO services from discovery through IND filing and commercial supply. The company plans to use the new financing to improve core technology platforms (including targeted ligand discovery), upgrade high-throughput screening for innovative RDCs, and accelerate clinical development of multiple pipelines—especially alpha-emitting RDC drugs. C Ray is also progressing IIT/clinical trials and overseas business development while aiming to scale its global service and commercialization capabilities.

Total raised

$100M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2024